Company news

Alnylam Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference

November 4, 2026

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

November 3, 2026

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

October 29, 2026

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

October 23, 2026

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

October 15, 2026

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

September 29, 2026

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

August 30, 2026

Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

August 24, 2026

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

July 30, 2026

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

July 16, 2026

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

July 15, 2026

Alnylam to Host Tenth "RNAi Roundtable" Webcast Series

June 12, 2026

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

June 3, 2026

Alnylam Issues 2025 Corporate Responsibility Report

May 19, 2026

ULTOMIRIS Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

May 15, 2026

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

May 12, 2026

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

May 4, 2026

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

April 29, 2026

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

April 15, 2026

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

March 29, 2026

Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis

March 24, 2026

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

March 23, 2026

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 11, 2026

Alnylam to Webcast TTR Investor Webinar

March 9, 2026

Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development

March 5, 2026

Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors

March 3, 2026

Alnylam Receives Positive Recommendation From Canada's Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (vutrisiran injection), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis

March 2, 2026

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

February 22, 2026

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

February 11, 2026

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

January 28, 2026

Adimab Reports Strong Partnering Year for 2025

January 12, 2026

Alnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact

January 11, 2026

Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical

January 7, 2026

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues

December 18, 2025

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

December 16, 2025

Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis

December 16, 2025

Annual Changes to the Nasdaq-100 Index®

December 12, 2025

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

December 10, 2025

Alnylam Pharmaceuticals Announces Changes to Board of Directors

December 2, 2025

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

November 7, 2025

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

November 3, 2025

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

October 29, 2025

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

October 15, 2025

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

September 30, 2025

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

September 27, 2025

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

September 8, 2025

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

September 7, 2025

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM

August 30, 2025

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

August 30, 2025

Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 89 decks. Every deck is listed under its year.